Press release
Lawsuit filed for Investors who lost money with shares of Zoetis Inc. (NYSE: ZTS)
A lawsuit was filed on behalf of investors in Zoetis Inc. (NYSE: ZTS) shares over alleged securities laws violations.
Investors who purchased shares of Zoetis Inc. (NYSE: ZTS) have certain options and for certain investors are short and strict deadlines running. Deadline: July 27, 2026. NYSE: ZTS investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Parsippany, NJ based Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. Zoetis Inc. Reported that its annual Total Revenue rose from over $9.25 billion in 2024 to over $9.46 billion in 2025, and that its Net Income increased from over $2.48 billion in in 2024 to over $2.67 billion in 2024.
On August 5, 2025, Zoetis Inc. released its second quarter 2025 financial results, allegedly revealing weakening demand trends within its companion animal portfolio.
On November 4, 2025, Zoetis Inc. released third quarter 2025 financial results, allegedly disclosing continued weakness in Librela sales and increased competitive pressure in dermatology and parasiticides.
On February 12, 2026, Zoetis Inc. released its fourth quarter and full year 2025 financial results and provided 2026 guidance reflecting further slowing growth. According to the complaint, Zoetis acknowledged increasing competitive pressures in parasiticides and dermatology.
Then on May 7, 2026, Zoetis Inc. reported first quarter 2026 financial results, allegedly disclosing slowing overall revenue growth, declining companion animal sales performance, and worsening results across its key dermatology and parasiticides franchises as competition intensified.
Shares of Zoetis Inc. (NYSE: ZTS) declined from $177.00 per share on March 10, 2025, to as low as $72.38 per share on May 15, 2026.
The plaintiff claims that between January 14, 2025 and May 6, 2026, the Defendants made materially false and misleading statements concerning the growth, competitive positioning, market share, and veterinarian adoption of key products within the Companion Animal segment while failing to disclose that veterinarian prescription growth and adoption of Zoetis' Librela, a canine pain treatment, were sharply weakening as clinicians became more cautious following FDA safety warnings concerning serious neurological complications in dogs, that Zoetis' Simparica Trio was losing significant market share to a lower priced competing canine parasiticide with broader indicated use in a slowing overall market, and that Zoetis' dermatology products, Apoquel and Cytopoint, were losing substantial market share to a newly launched competing canine treatment.
Those who purchased shares of Zoetis Inc. (NYSE: ZTS) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lawsuit filed for Investors who lost money with shares of Zoetis Inc. (NYSE: ZTS) here
News-ID: 4531903 • Views: …
More Releases from Shareholders Foundation, Inc.
NASDAQ: REPL Investor Alert: Lawsuit against Replimune Group, Inc. seeks to reco …
An investor, who purchased shares of Replimune Group, Inc. (NASDAQ: REPL), filed a lawsuit over alleged violations of Federal Securities Laws by Replimune Group, Inc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Replimune Group, Inc. (NASDAQ: REPL) have certain options and for certain investors are short and strict deadlines running. Deadline: October 5, 2026. NASDAQ: REPL investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
NYSE: BMI Long Term Investor Alert: Investigation over potential Wrongdoing by c …
An investigation was announced for long-term investors in shares of Badger Meter, Inc. (NYSE: BMI) concerning potential breaches of fiduciary duties by certain directors of Badger Meter, Inc. was announced.
Investors who are current long term investors in Badger Meter, Inc. (NYSE: BMI) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term…
Lawsuit Alert: Investors who lost money with ARS Pharmaceuticals, Inc. (NASDAQ: …
An investor, who purchased shares of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), filed a lawsuit over alleged violations of Federal Securities Laws by ARS Pharmaceuticals, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) have certain options and for certain investors are short and strict deadlines running. Deadline: October 5, 2026. NASDAQ: SPRY investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Investigation Alert: Investors in GeneDx Holdings Corp. (NASDAQ: WGS) should con …
An investigation was announced for current long-term investors in shares of GeneDx Holdings Corp. (NASDAQ: WGS) concerning potential breaches of fiduciary duties by certain directors and officers of GeneDx Holdings Corp.
Investors who are current long term investors in GeneDx Holdings Corp. (NASDAQ: WGS) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term…
More Releases for Zoetis
Livestock Monitoring Market Set for Strong Expansion | • Allflex • Zoetis
➤ Global Livestock Monitoring Market Research Report (2026-2033)
The Worldwide "Livestock Monitoring Market" Research Report 2026 delivers a comprehensive, decision-ready analysis of the global Livestock Monitoring industry, offering clear insights into current market conditions and future growth potential. Developed using a robust research framework, the report combines validated data models, expert analysis, and real-world market intelligence to support strategic decision-making.
This study evaluates the complete market ecosystem, including industry development plans, policy…
Medicated Feed Additives Market is Booming Worldwide | • Cargill • Zoetis
Worldwide Market Reports has added a new research study on "Medicated Feed Additives Market" is projected to experience substantial growth in the coming years. This report provides a comprehensive analysis of the market landscape using an integrated approach that includes research methodology, market size evaluation, data compilation, and insights gathered from multiple credible sources.
The study covers critical market elements such as market dynamics, drivers, restraints, challenges, threats, growth opportunities, development…
Aquaculture Vaccines Market Is Going to Boom |• Zoetis • Elanco
According to Worldwide Market Reports (WMR) highlights that the "Aquaculture Vaccines Market" is projected to experience substantial growth in the coming years. This report provides a comprehensive analysis of the market landscape using an integrated approach that includes research methodology, market size evaluation, data compilation, and insights gathered from multiple credible sources.
The study covers critical market elements such as market dynamics, drivers, restraints, challenges, threats, growth opportunities, development trends, technological…
Microfluidics Market Size to Reach USD 1028.8 million by 2028 | Zoetis, PerkinEl …
The latest report on Microfluidics Market highlights the elements enhancing the developmental scope of the market as well as inhibitors challenging its growth during the forecast period. The study presents information on market segments in terms of product terrain, structure outlook, and distribution channel.
For More Details on This Report @ https://www.marketstudyreport.com/reports/global-microfluidics-market-research-report-2023
Global Microfluidics Market Size was estimated at USD 776.6 million in 2022 and is projected to reach USD…
Dexmedetomidine Market to See Booming Growth | Pfizer, Zoetis, Vetoquinol
The latest study released on the Global Dexmedetomidine Market by AMA Research evaluates market size, trend, and forecast to 2027. The Dexmedetomidine market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and other key people to have ready-to-access and self-analyzed study to help understand market trends, growth drivers, opportunities and upcoming challenges and about the competitors.
Key Players in This Report…
Spectinomycin (CAS 1695-77-8) Market to Witness Huge Growth by Key Players: Luka …
The Spectinomycin (CAS 1695-77-8) research report combines vital data incorporating the competitive landscape, global, regional, and country-specific market size, market growth analysis, market share, recent developments, and market growth in segmentation. Furthermore, the Spectinomycin (CAS 1695-77-8) research report offers information and thoughtful facts like share, revenue, historical data, and global market share. It also highlights vital aspects like opportunities, driving, product scope, market overview, and driving force.
Download FREE Sample Report…
